Skip to main content
Premium Trial:

Request an Annual Quote

PEOPLE: Human Genome Sciences Snags Jerry Karabelas and AxCell Recruits New Board Member

NEW YORK, April 17 - Gene Network Sciences, an Ithaca, NY-based computational biology company, said today that Stuart Kauffman has joined its board of directors.


Kauffman is a consultant to Los Alamos National Laboratories, a founding member of the Santa Fe Institute, and chief scientific officer of BiosGroup, a consulting and software development company.


Gene Network Sciences uses gene-expression and proteomics data to build computer models of gene and protein circuits. It combines these models with inferential bioinformatics and data mining tools in order to develop drug targets and test potential drugs. 


The company's main disease focus is colon cancer, and it has developed software to improve data extraction from microarray experiments.


GNS said that Methylgene senior vice president Jeffrey Besterman and Princeton molecular biologist Daniel Notterman had also joined the company's scientific advisory board.


Human Genome Sciences said on April 15 that it had appointed Jerry Karabelas to its board of directors.


Karabelas was most recently at the investment company Care Capital. Previously, he was founder and chair of the Novartis BioVenture Fund.


AxCell Biosciences said on April 12 that it had appointed Jill Mesirov to its scientific advisory board.


Mesirov is chief information officer and director of bioinformatics and computational biology at the Whitehead Institute. She also has an appointment at Boston University as adjunct professor of bioinformatics.


She is known for her expertise in developing computational biology algorithms for gene-expression data, sequence-homology searching, protein folding, and other areas.


Mesirov joins Axel Ullrich, Tony Hunter, and Marius Sudol on AxCell's growing scientific advisory board.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.